Judith McGarry, Author at Aurion Biotech

Name	Provider	Purpose	Expires
pint-checkbox-non-necessary	aurionbiotech.com	Remembers your selected cookie consent preference	3 months
pint-cookies-accepted	aurionbiotech.com	Remembers that you have made a cookie preference	1 Year

Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough

Annual Awards Program Recognizes Innovation in Global Life Sciences and BiotechnologySEATTLE, CAMBRIDGE and TOKYO – November 8, 2023 – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has been selected as “Regenerative Therapeutics Company of the Year” in the third annual BioTech Breakthrough Awards program...

The Importance of Teamwork

by Greg Kunst, CEOIt’s said that biotech is a “team sport.” Certainly, coordination, collaboration and consistently high performance are just some of the teamwork qualities that the Aurion Biotech team displayed in the months leading up to this week’s massively significant milestone, where we had the privilege of treating our first subjects in our ABA-1...

Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

Allogeneic Cell Therapy for the Treatment of Corneal Edema Secondary to Corneal Endothelial DysfunctionSeattle, Cambridge, Tokyo–(BUSINESS WIRE)— 24 October 2023—Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of...

Aurion Biotech Wins Clinical Advance of the Year Award at Biotech Week Boston

Recognition for its innovative cell therapy for corneal endothelial diseasesSeptember 19, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has received the Clinical Advance of the Year award from Biotech Week Boston.“Aurion Biotech is advancing a game-changing cell...

Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Efficacy data from Escalón study shows improvements in central corneal thickness and best corrected visual acuity May 2, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS)...

March Milestone

By Greg Kunst, CEO A lot of things seem to happen in March – Caesar’s assassination, Shakespeare’s Ides (a fortune-teller’s warning of the aforementioned assassination), the Spring Equinox, and (of course) March Madness.But Aurion’s most recent March Milestone augurs only good things – especially for the millions of patients around the world who suffer from...

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

First approval in the world forallogeneic cell therapy to treat corneal endothelial disease March 23, 2023 – Seattle, Cambridge MA and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMD A),...

Aurion Biotech Expands Its Leadership Team

Regulatory Affairs and Clinical Operations Vice Presidents Add Key Expertise as Company Prepares to Initiate U.S. Clinical Trials November 30, 2022 – Seattle, Boston and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Sherita Hall as vice president, clinical operations...

Living Our Values at Aurion Biotech

As others have said both are valid and will do the trick. I'm not 100% convinced that they are identical though. If you have some style cascading going on then they could in theory produce different results since they are effectively override.

ARCHIVE